New results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study showed that a combination of pembrolizumab and concurrent chemoradiotherapy (CCRT) continues to ...
A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results